Medlab Clinical (Medlab Clinical) EBITDA Margin % : -4,140.63% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medlab Clinical's EBITDA for the six months ended in Dec. 2023 was $-1.33 Mil. Medlab Clinical's Revenue for the six months ended in Dec. 2023 was $0.03 Mil. Therefore, Medlab Clinical's EBITDA margin for the quarter that ended in Dec. 2023 was -4,140.63%.

Medlab Clinical EBITDA Margin % Historical Data

The historical data trend for Medlab Clinical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical EBITDA Margin % Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBITDA Margin %

Get a 7-Day Free Trial

-146.31

-433.03

-260.81

-584.35

-641.07

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial												-865.27	-439.77	-733.66	-452.79	-4,140.63

Competitive Comparison of Medlab Clinical's EBITDA Margin %

For the Biotechnology subindustry, Medlab Clinical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's EBITDA Margin % falls into.

Medlab Clinical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medlab Clinical's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-3.84	/	0.599
	=	-641.07 %

Medlab Clinical's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.325	/	0.032
	=	-4,140.63 %

Medlab Clinical (OTCPK:MDBBF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Medlab Clinical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (Medlab Clinical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.